was a shareholder in stu many years ago, liked Tino so have followed him to see what he could do here, which looks like nothing (from a shareholder return perspective)
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
